0000905148-24-000849.txt : 20240301
0000905148-24-000849.hdr.sgml : 20240301
20240301191520
ACCESSION NUMBER: 0000905148-24-000849
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240228
FILED AS OF DATE: 20240301
DATE AS OF CHANGE: 20240301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RODRIGUEZ RAUL R
CENTRAL INDEX KEY: 0001190279
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29889
FILM NUMBER: 24712310
MAIL ADDRESS:
STREET 1: 1180 VETERANS BOULEVARD
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: RIGEL PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001034842
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 943248524
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 611 GATEWAY BOULEVARD, SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-624-1100
MAIL ADDRESS:
STREET 1: 611 GATEWAY BOULEVARD, SUITE 900
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
4
1
form4.xml
X0508
4
2024-02-28
0001034842
RIGEL PHARMACEUTICALS INC
RIGL
0001190279
RODRIGUEZ RAUL R
RIGEL PHARMACEUTICALS, INC.
611 GATEWAY BLVD, SUITE 900
SOUTH SAN FRANCISCO
CA
94080
true
true
CEO, President
false
Employee Stock Option (right to buy)
1.87
2024-02-28
4
A
0
300000
0
A
2033-01-26
Common Stock
300000
300000
D
Employee Stock Option (right to buy)
1.27
2024-02-28
4
A
0
300000
0
A
2034-01-23
Common Stock
300000
300000
D
The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 26, 2023. Thus, the exercise price of this option is $1.87 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met.
The Reporting Person was granted an option with a performance-based condition with respect to 300,000 shares of the issuer's common stock on January 23, 2024. Thus, the exercise price of this option is $1.27 (the closing price of the issuer's common stock on Nasdaq the date of grant). In light of the performance-based vesting condition of this grant, the grant was not reportable under Section 16 until the performance metric was satisfied. On February 28, 2024, it was determined that the performance metric had been met.
The option was fully vested on February 28, 2024, the date the determination was made that the performance metric had been met.
/s/ Raymond Furey (Attorney-in-Fact)
2024-03-01